GalNAc-Conjugated Antisense Compounds for Hepatocyte Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antisense compounds face challenges in achieving optimal uptake and activity in liver cells, particularly hepatocytes, due to limitations in delivery and stability, which affects their therapeutic efficacy.
Innovation Solution
Development of conjugated antisense compounds with cleavable moieties linked through phosphodiester bonds, utilizing GalNAc clusters for enhanced liver cell uptake, and modified galactosyl analogues for increased potency and stability, allowing for improved delivery and activity within hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antisense compounds are administered, then they can modulate target gene expression, but their uptake and activity in liver cells is insufficient
Solution Approach 1:
The patent employs GalNAc clusters as intermediary molecules that facilitate the delivery of antisense compounds to hepatocytes. The GalNAc moiety acts as a mediator that binds to the asialoglycoprotein receptor on liver cell surfaces, enabling efficient cellular uptake of the conjugated antisense compound while maintaining the compound's ability to modulate target gene expression.
Solution Approach 2:
The invention creates composite structures by conjugating antisense compounds with GalNAc clusters through phosphodiester bonds. This composite material combines the gene-silencing capability of antisense oligonucleotides with the liver-targeting specificity of GalNAc, resulting in a multifunctional therapeutic agent that achieves both efficient delivery and reliable therapeutic effect.
2Quantity of substance
If chemical modifications are made to enhance potency, then lower doses can be administered, but the compound structure becomes more complex
Solution Approach 1:
The patent utilizes phosphodiester bonds to conjugate GalNAc clusters to antisense compounds, creating a modular structure that can be systematically varied. By changing parameters such as the number of GalNAc units (typically 2-4), the length of the antisense sequence, and the specific phosphodiester linkage positions, the invention optimizes potency to achieve effective lower dosing while maintaining manageable structural complexity through standardized modular components.
3Duration of action of stationary object
If chemical modifications are made to increase resistance to degradation, then clearance from the body is reduced, but the synthesis and manufacturing become more difficult
Solution Approach 1:
The invention segments the antisense compound into modular components connected by phosphodiester bonds, including the antisense oligonucleotide core and GalNAc cluster conjugates. This segmentation allows each component to be synthesized separately using established oligonucleotide chemistry methods, then assembled through well-characterized phosphodiester coupling reactions, thereby achieving enhanced stability and reduced clearance while maintaining ease of manufacture through modular assembly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugated antisense compounds demonstrate enhanced potency and stability, leading to increased delivery and activity in liver tissue while maintaining tolerability, thereby improving therapeutic outcomes.
Implementation Method 1
compounds comprising clusters of three N-acetylgalactosamine (GalNAc) ligands are capable of binding to the ASGP-R, resulting in uptake of the compound into the cell
Implementation Method 2
conjugated antisense compounds with cleavable moieties linked through phosphodiester bonds
Implementation Method 3
Chemical modifications increasing the resistance to degradation result in slower clearance from the body
Data Source
AI summary
Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.